Dermira Ends Acne Program After Phase III Failure, Tries To Keep Focus On Hyperhidrosis Drug

FDA approval for DRM04 in hyperhidrosis is expected at the end of June, but Phase III data for DRM01 in acne was the main event for investors. CEO Tom Wiggans said Dermira will try to understand what went wrong, while staying focused on DRM04 commercialization and lebrikizumab in Phase IIb.

Dermira Inc. Chairman and CEO Tom Wiggans did not pull any punches when talking about negative Phase III results for acne candidate olumacostat glaseratil (DRM01) March 5, instead being very upfront that the CLAREOS-1 and CLAREOS-2 studies failed and did not merit continued development of the drug.

Wiggans told Scrip that while Dermira was "stunned" by the results – the most anticipated milestone for the company's investors...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

06 Jun 2025

• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.